HR-Positive Advances Highlight the Good News in Breast Cancer

Jennifer W. Fink
Published: Thursday, Mar 15, 2018
Lee S. Schwartzberg,
MD, FACP

Lee S. Schwartzberg, MD, FACP
Recent advancements in the field of breast cancer are reshaping the treatment paradigm for subsets of patients with the disease, bringing new therapies and strategies into focus, according to experts who participated in an OncLive Peer Exchange® panel.

“I think the science in breast cancer is really making tangible differences in our patients’ lives now and that’s exciting,” said Lee S. Schwartzberg, MD.

Hormone-Driven Breast Cancer

Three CDK4/6 inhibitors are now approved for patients with metastatic, HR-positive, HER2- negative breast cancer. Palbociclib (Ibrance) was the first agent approved in this drug class in 2015, followed by abemaciclib (Verzenio) and ribociclib (Kisqali) in 2017. These therapies have been targeted for postmenopausal women.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Community Practice Connections™: Evolving Applications for PARP Inhibitors in Ovarian Cancer: Building on a Solid FoundationAug 15, 20191.5
Publication Bottom Border
Border Publication
x